Details of the Drug

General Information of Drug (ID: DMKQTBA)

Drug Name

Diphenhydramine

Synonyms

diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl; Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM

Indication

Disease Entry	ICD 11	Status	REF
Meniere disease	AB31.0	Approved	[1]

Therapeutic Class

Antiallergic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

255.35

Topological Polar Surface Area (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 9.7 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 36% [2]
Clearance: The clearance of drug is 600-1300 mL/min [4]
Elimination: Only about 1% of a single dose is excreted unchanged in urine [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.4 - 9.3 hours [6]
Metabolism: The drug is metabolized via the amine moiety of the N,N-didesmethyl metabolite [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.26202 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.19% [9]
Vd: The volume of distribution (Vd) of drug is 3.3-6.8 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 1000 mg/mL [3]

Chemical Identifiers

Formula: C17H21NO
IUPAC Name: 2-benzhydryloxy-N,N-dimethylethanamine
Canonical SMILES: CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
InChI: InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
InChIKey: ZZVUWRFHKOJYTH-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3100
ChEBI ID: CHEBI:4636
CAS Number: 58-73-1
DrugBank ID: DB01075
TTD ID: D01FGR
VARIDT ID: DR00385
INTEDE ID: DR0514
ACDINA ID: D00203

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[10], [11]
Histamine N-methyltransferase (HNMT)	TT2B6EV	HNMT_HUMAN	Inhibitor	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[15]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Meniere disease

ICD Disease Classification

AB31.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.62E-01	2.57E-02	1.10E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Prostaglandin G/H synthase 1 (COX-1)	DME	PTGS1	2.19E-01	1.72E-01	5.16E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Diphenhydramine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[52]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[52]
Dronedarone	DMA8FS5	Moderate	Increased risk of prolong QT interval by the combination of Diphenhydramine and Dronedarone.	Angina pectoris [BA40]	[53]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[54]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Cariprazine.	Bipolar disorder [6A60]	[54]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Diphenhydramine when combined with Acetylcholine.	Cataract [9B10]	[55]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[56]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[56]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Diphenhydramine and Isocarboxazid.	Depression [6A70-6A7Z]	[57]
OPC-34712	DMHG57U	Major	Decreased metabolism of Diphenhydramine caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[58]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Doxepin.	Depression [6A70-6A7Z]	[52]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Diphenhydramine and Esketamine.	Depression [6A70-6A7Z]	[53]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Mepenzolate.	Digestive system disease [DE2Z]	[54]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Solifenacin.	Functional bladder disorder [GC50]	[54]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Diphenhydramine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[59]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Diphenhydramine when combined with Pilocarpine.	Glaucoma [9C61]	[55]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Diphenhydramine and Procarbazine.	Hodgkin lymphoma [2B30]	[57]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Diphenhydramine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[54]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Diphenhydramine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[61]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Diphenhydramine when combined with R0-93877.	Irritable bowel syndrome [DD91]	[62]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Diphenhydramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[63]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Diphenhydramine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[64]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Diphenhydramine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[65]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Diphenhydramine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[66]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Diphenhydramine and Flibanserin.	Mood disorder [6A60-6E23]	[67]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Diphenhydramine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[68]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Phenindamine.	Nasopharyngitis [CA00]	[54]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Diphenhydramine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[69]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Diphenhydramine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[70]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Diphenhydramine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[71]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Methylscopolamine.	Peptic ulcer [DA61]	[54]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Diphenhydramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[72]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[54]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Diphenhydramine when combined with Quetiapine.	Schizophrenia [6A20]	[73]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Diphenhydramine when combined with Aripiprazole.	Schizophrenia [6A20]	[73]
Iloperidone	DM6AUFY	Moderate	Antagonize the effect of Diphenhydramine when combined with Iloperidone.	Schizophrenia [6A20]	[73]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Diphenhydramine when combined with Paliperidone.	Schizophrenia [6A20]	[73]
Molindone	DMAH70G	Moderate	Antagonize the effect of Diphenhydramine when combined with Molindone.	Schizophrenia [6A20]	[73]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Diphenhydramine when combined with Thiothixene.	Schizophrenia [6A20]	[73]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Diphenhydramine when combined with Asenapine.	Schizophrenia [6A20]	[73]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Diphenhydramine when combined with Pimozide.	Schizophrenia [6A20]	[73]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[52]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Diphenhydramine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[54]
Bretylium	DM1FX74	Moderate	Increased risk of prolong QT interval by the combination of Diphenhydramine and Bretylium.	Ventricular tachyarrhythmia [BC71]	[53]
-----------


⏷ Show the Full List of 45 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Butylparaben	E00142	7184	Antimicrobial preservative
D&C red no. 27	E00381	83511	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 30	E00456	3000709	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Malic acid	E00018	525	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben	E00149	7456	Antimicrobial preservative
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose	E00370	71485	Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium biphosphate	E00296	24454	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Edetate calcium disodium	E00487	6093170	Complexing agent
Eisenoxyd	E00585	56841934	Colorant
Ethanethiol	E00116	6343	Flavoring agent
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Fructose	E00447	2723872	Flavoring agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 2000	E00649	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium citrate	E00225	13344	Alkalizing agent; Buffering agent; Complexing agent
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sodium propionate	E00445	2723816	Antimicrobial preservative
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant
--------------------


⏷ Show the Full List of 70 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Diphenhydramine 25 mg capsule	25 mg	Oral Capsule	Oral
Diphenhydramine 50 mg capsule	50 mg	Oral Capsule	Oral
Diphenhydramine 12.5 mg tablet	12.5 mg	Disintegrating Oral Tablet	Oral
Diphenhydramine 12.5 mg tablet	12.5 mg	Chewable Tablet	Oral
Diphenhydramine 50 mg tablet	50 mg	Oral Tablet	Oral
Diphenhydramine 25 mg tablet	25 mg	Disintegrating Oral Tablet	Oral
Diphenhydramine 25 mg tablet	25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	NIH ODS Vitamin E Fact Sheet for Health Professionals
3	BDDCS applied to over 900 drugs
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Electronic Medicines Compendium: Boots Sleepeaze (diphenhydramine hydrochloride) 50mg Tablets Monograph
6	Electronic Medicines Compendium: Nytol One-A-Night (diphenhydramine hydrochloride) Monograph
7	Miura Y, Chishima S, Takeyama S: Studies of metabolic pathways of trimebutine by simultaneous administration of trimebutine and its deuterium-labeled metabolite. Drug Metab Dispos. 1989 Jul-Aug;17(4):455-62.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
11	Histamine as an autocrine regulator of leukemic cell proliferation. Leuk Lymphoma. 2000 Jan;36(3-4):367-73.
12	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
13	Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
14	Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
17	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
18	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
19	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
21	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
22	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
23	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
24	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
25	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
26	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
27	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
28	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
29	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
30	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
31	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
32	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
33	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
34	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
35	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
36	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
37	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
38	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
39	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
40	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
41	Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
42	Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84.
43	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
44	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
45	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
46	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
47	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
48	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
49	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
50	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
51	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
52	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
53	Cerner Multum, Inc. "Australian Product Information.".
54	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
55	Multum Information Services, Inc. Expert Review Panel.
56	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
57	Canadian Pharmacists Association.
58	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
59	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
60	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
61	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
62	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
63	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
64	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
65	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
66	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
67	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
68	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
69	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
70	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
71	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
72	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
73	Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]